Engineers at the Massachusetts Institute of Technology (MIT) have developed an innovative method that represents a major breakthrough in the treatment of esophageal diseases. This new technology allows medications to be delivered directly to the esophageal mucosa and effectively penetrate the tissue, which has previously been a significant challenge in medical practice.<\/p>\n
The biological structure and function of the esophagus present natural barriers to treatment. Because any liquid or food passes through the esophagus in seconds, ingested medicine barely has time to make contact with the tissue. Compounding this issue, the esophagus is lined with a stratified squamous epithelium that is highly impermeable to external molecules. Due to this obstacle, for severe inflammatory diseases of the esophagus such as Crohn’s disease or eosinophilic esophagitis, physicians are forced to prescribe systemic medications. The latter, however, often cause serious side effects throughout the entire body. The alternative route\u2014direct injection of the drug into the esophagus\u2014is painful and inconvenient for the patient, requiring specialized intervention in a clinical setting.<\/p>\n
The MIT research team, led by Robert Langer and Giovanni Traverso, created a specialized gel-based oral formula. The system combines two main components: a hydrogel derived from polysaccharides and bile acid salts. Thanks to its viscous consistency, the hydrogel adheres to the walls of the esophagus as a thin layer during swallowing and remains there for a certain period. The bile acid salts act as highly effective excipients or auxiliary substances. They temporarily relax the tight intercellular junctions in the epithelium, opening a safe corridor for large drug molecules to penetrate deeply into the tissue.<\/p>\n
To develop and test this new platform, the engineers built a specialized screening system that precisely mimics the anatomy of the esophagus. By applying medications to tissue placed between two vertical plates, they were able to measure exactly how much of the active substance crossed the barrier. Tests conducted on animals demonstrated that this formula can even deliver complex monoclonal antibodies, such as Infliximab, which is used to treat autoimmune disorders.<\/p>\n
Currently, the scientists are working on optimizing the gel so that it remains on the esophagus for precisely the duration needed for the drug to be absorbed, while causing no discomfort to the patient. According to the researchers, this achievement establishes a unique foundation for targeted esophageal therapy, which was previously impossible due to the lack of appropriate technological tools. In the future, this approach will significantly reduce the systemic side effects of heavy medications and streamline the treatment process for gastroenterological patients.<\/p>\n